1
|
Yang X, Li Z, Xu W, Zhu G, Feng X, Zhang J, Zhao H, Chen Y, Kong J, Mai W, Li LS, Pippel DJ, Ren P, Deng X. Hindered Biaryl Bond Construction and Subsequent Diastereomeric Crystallization to Produce an Atropisomeric Covalent KRAS G12C Inhibitor ARS-2102. Org Process Res Dev 2022. [DOI: 10.1021/acs.oprd.2c00335] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Affiliation(s)
- Xiaogen Yang
- STA Pharmaceutical Co., Ltd., a WuXi AppTec Company, 288 Fute Zhong Road, Waigaoqiao Pilot Free Trade Zone, Shanghai 200131, China
| | - Zhiwen Li
- STA Pharmaceutical Co., Ltd., a WuXi AppTec Company, 288 Fute Zhong Road, Waigaoqiao Pilot Free Trade Zone, Shanghai 200131, China
| | - Wenwen Xu
- STA Pharmaceutical Co., Ltd., a WuXi AppTec Company, 288 Fute Zhong Road, Waigaoqiao Pilot Free Trade Zone, Shanghai 200131, China
| | - Guanming Zhu
- STA Pharmaceutical Co., Ltd., a WuXi AppTec Company, 288 Fute Zhong Road, Waigaoqiao Pilot Free Trade Zone, Shanghai 200131, China
| | - Xiantong Feng
- WuXi AppTec Co., Ltd., 168 Nanhai Road, TEDA, Tianjin 300457, China
| | - Jun Zhang
- WuXi AppTec Co., Ltd., 168 Nanhai Road, TEDA, Tianjin 300457, China
| | - Hongbin Zhao
- WuXi AppTec Co., Ltd., 168 Nanhai Road, TEDA, Tianjin 300457, China
| | - Yuyin Chen
- WuXi AppTec Co., Ltd., 168 Nanhai Road, TEDA, Tianjin 300457, China
| | - Jianshe Kong
- WuXi AppTec Co., Ltd., 168 Nanhai Road, TEDA, Tianjin 300457, China
| | - Wanping Mai
- Wellspring Biosciences Inc., 10770 Wateridge Cir. Unit 120, San Diego, California 92121, United States
| | - Lian-Sheng Li
- Wellspring Biosciences Inc., 10770 Wateridge Cir. Unit 120, San Diego, California 92121, United States
| | - Daniel J. Pippel
- Janssen Research & Development LLC, 3210 Merryfield Row, San Diego, California 92121, United States
| | - Pingda Ren
- Wellspring Biosciences Inc., 10770 Wateridge Cir. Unit 120, San Diego, California 92121, United States
| | - Xiaohu Deng
- Wellspring Biosciences Inc., 10770 Wateridge Cir. Unit 120, San Diego, California 92121, United States
| |
Collapse
|
2
|
Luo RS, Mao SN, Liu CJ, Zhou ZX, Huang ZY. SYNTHESIS, X-RAY STRUCTURE ANALYSIS, AND VIBRATIONAL SPECTRAL STUDIES OF 1-(3-((6-BROMOPYRIDO[2,3-d]PYRIMIDIN-4-YL) OXY)PHENYL)-3-CYCLOPENTYLUREA. J STRUCT CHEM+ 2022. [DOI: 10.1134/s002247662201005x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
3
|
Choudhary S, Doshi A, Luckett-Chastain L, Ihnat M, Hamel E, Mooberry SL, Gangjee A. Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer. Bioorg Med Chem 2021; 35:116061. [PMID: 33647840 PMCID: PMC7995636 DOI: 10.1016/j.bmc.2021.116061] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2020] [Revised: 01/28/2021] [Accepted: 02/01/2021] [Indexed: 12/12/2022]
Abstract
The efficacy of quinazoline-based antiglioma agents has been attributed to their effects on microtubule dynamics.1,2 The design, synthesis and biological evaluation of quinazolines as potent inhibitors of multiple intracellular targets, including microtubules and multiple RTKs, is described. In addition to the known ability of quinazolines 1 and 2 to cause microtubule depolymerization, they were found to be low nanomolar inhibitors of EGFR, VEGFR-2 and PDGFR-β. Low nanomolar inhibition of EGFR was observed for 1-3 and 9-10. Compounds 1 and 4 inhibited VEGFR-2 kinase with activity better than or equal to that of sunitinib. In addition, compounds 1 and 2 had similar potency to sunitinib in the CAM angiogenesis assay. Multitarget activities of compounds in the present study demonstrates that the quinazolines can affect multiple pathways and could lead to these agents having antitumor potential caused by their activity against multiple targets.
Collapse
Affiliation(s)
- Shruti Choudhary
- Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, PA 15282, United States
| | - Arpit Doshi
- Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, PA 15282, United States
| | - Lerin Luckett-Chastain
- College of Pharmacy, University of Oklahoma Health Science Center, 1110 North Stonewall, Oklahoma City, OK 73117, United States
| | - Michael Ihnat
- College of Pharmacy, University of Oklahoma Health Science Center, 1110 North Stonewall, Oklahoma City, OK 73117, United States
| | - Ernest Hamel
- Molecular Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, United States
| | - Susan L Mooberry
- Department of Pharmacology, Mays Cancer Center, University of Texas Health Science Center, San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, United States
| | - Aleem Gangjee
- Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, PA 15282, United States.
| |
Collapse
|
4
|
Qin J, Li Z, Ma S, Ye L, Jin G, Su W. One-pot cascade ring enlargement of isatin-3-oximes to 2,4-dichloroquinazolines mediated by bis(trichloromethyl)carbonate and triarylphosphine oxide. PHOSPHORUS SULFUR 2020. [DOI: 10.1080/10426507.2020.1782910] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- Jinjing Qin
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, P.R. China
| | - Zhenhua Li
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, P.R. China
| | - Shengzhe Ma
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, P.R. China
| | - Lixian Ye
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, P.R. China
| | - Guoqiang Jin
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, P.R. China
| | - Weike Su
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, P.R. China
| |
Collapse
|
5
|
Hong CM, Xu Y, Chung JYL, Schultz DM, Weisel M, Varsolona RJ, Zhong YL, Purohit AK, He CQ, Gauthier DR, Humphrey GR, Maloney KM, Lévesque F, Wang Z, Whittaker AM, Sirota E, McMullen JP. Development of a Commercial Manufacturing Route to 2-Fluoroadenine, The Key Unnatural Nucleobase of Islatravir. Org Process Res Dev 2020. [DOI: 10.1021/acs.oprd.0c00304] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Cynthia M. Hong
- Process Research & Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Yingju Xu
- Process Research & Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - John Y. L. Chung
- Process Research & Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Danielle M. Schultz
- Process Research & Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Mark Weisel
- Process Research & Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Richard J. Varsolona
- Process Research & Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Yong-Li Zhong
- Process Research & Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Akasha K. Purohit
- Process Research & Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Cyndi Q. He
- Process Research & Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Donald R. Gauthier
- Process Research & Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Guy R. Humphrey
- Process Research & Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Kevin M. Maloney
- Process Research & Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - François Lévesque
- Process Research & Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Zhixun Wang
- Process Research & Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Aaron M. Whittaker
- Process Research & Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Eric Sirota
- Process Research & Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Jonathan P. McMullen
- Process Research & Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| |
Collapse
|
6
|
Han S, Sang Y, Wu Y, Tao Y, Pannecouque C, De Clercq E, Zhuang C, Chen FE. Molecular Hybridization-Inspired Optimization of Diarylbenzopyrimidines as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors with Improved Activity against K103N and E138K Mutants and Pharmacokinetic Profiles. ACS Infect Dis 2020; 6:787-801. [PMID: 31599568 DOI: 10.1021/acsinfecdis.9b00229] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Molecular hybridization is a powerful strategy in drug discovery. A series of novel diarylbenzopyrimidine (DABP) analogues were developed by the hybridization of FDA-approved drugs etravirine (ETR) and efavirenz (EFV) as potential HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs). Substituent modifications resulted in the identification of new DABPs with the combination of the strengths of the two drugs, especially compound 12d, which showed promising activity toward the EFV-resistant K103N mutant. 12d also had a favorable pharmacokinetic (PK) profile with liver microsome clearances of 14.4 μL/min/mg (human) and 33.2 μL/min/mg (rat) and an oral bioavailability of 15.5% in rat. However, its activity against the E138K mutant was still unsatisfactory; E138K is the most prevalent NNRTI resistance-associated mutant in ETR treatment. Further optimizations resulted in a highly potent compound (12z) with no substituents on the phenyl ring and a 2-methyl-6-nitro substitution pattern on the 4-cyanovinyl-2,6-disubstitued phenyl motif. The antiviral activity of this compound was much higher than those of ETR and EFV against the WT, E138K, and K103N variants (EC50 = 3.4, 4.3, and 3.6 nM, respectively), and the cytotoxicity was decreased while the selectivity index (SI) was increased. In particular, this compound exhibited acceptable intrinsic liver microsome stability (human, 34.5 μL/min/mg; rat, 33.2 μL/min/mg) and maintained the good PK profile of its parent compound EFV and showed an oral bioavailability of 16.5% in rat. Molecular docking and structure-activity relationship (SAR) analysis provided further insights into the binding of the DABPs with HIV-1 reverse transcriptase and provided a deeper understanding of the key structural features responsible for their interactions.
Collapse
Affiliation(s)
- Sheng Han
- Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai 200433, People’s Republic of China
- Shanghai Engineering Center of Industrial Asymmetric Catalysis for Chiral Drugs, Shanghai 200433, People’s Republic of China
| | - Yali Sang
- Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai 200433, People’s Republic of China
- Shanghai Engineering Center of Industrial Asymmetric Catalysis for Chiral Drugs, Shanghai 200433, People’s Republic of China
| | - Yan Wu
- Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai 200433, People’s Republic of China
- Shanghai Engineering Center of Industrial Asymmetric Catalysis for Chiral Drugs, Shanghai 200433, People’s Republic of China
| | - Yuan Tao
- Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai 200433, People’s Republic of China
- Shanghai Engineering Center of Industrial Asymmetric Catalysis for Chiral Drugs, Shanghai 200433, People’s Republic of China
| | | | - Erik De Clercq
- Rega Institute for Medical Research, KU Leuven, Herestraat 49, B-3000 Leuven, Belgium
| | - Chunlin Zhuang
- Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai 200433, People’s Republic of China
- Shanghai Engineering Center of Industrial Asymmetric Catalysis for Chiral Drugs, Shanghai 200433, People’s Republic of China
| | - Fen-Er Chen
- Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai 200433, People’s Republic of China
- Shanghai Engineering Center of Industrial Asymmetric Catalysis for Chiral Drugs, Shanghai 200433, People’s Republic of China
| |
Collapse
|
7
|
Wang J, Li YH, Pan SC, Li MF, Du W, Yin H, Li JH. Efficient Phosphorus-Free Chlorination of Hydroxy Aza-Arenes and Their Application in One-Pot Pharmaceutical Synthesis. Org Process Res Dev 2020. [DOI: 10.1021/acs.oprd.9b00407] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Jian Wang
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, P. R. China
- School of Pharmacy, Hangzhou Medical College, Hangzhou 310053, P. R. China
| | - Yan-Hui Li
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, P. R. China
| | - Song-Cheng Pan
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, P. R. China
| | - Ming-Fang Li
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, P. R. China
| | - Wenting Du
- School of Pharmacy, Hangzhou Medical College, Hangzhou 310053, P. R. China
| | - Hong Yin
- School of Pharmacy, Hangzhou Medical College, Hangzhou 310053, P. R. China
| | - Jing-Hua Li
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, P. R. China
| |
Collapse
|
8
|
Lin L, Chen X, Zhao J, Lin S, Ma G, Liao X, Feng P. Facile One-pot Protocol of Derivatization Nitropyridines: Access to 3-Acetamidopyridin-2-yl 4-methylbenzenesulfonate Derivatives. HETEROCYCL COMMUN 2019. [DOI: 10.1515/hc-2019-0017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
AbstractThis paper discloses an efficient one-pot protocol to convert easily accessible 3-nitropyridines to 3-acetamidopyridin-2-yl 4-methylbenzenesulfonate derivatives which are core structures of many pharmaceutical molecules. The strategy successfully combined a three-step reaction in one pot via progressively adding different reactants at rt. The reaction displays good functional group tolerance and regioselectivity. Structurally diversified 3-nitropyridine could be time-efficiently (3.5 h) derivatized to various functional 2-O,3-N-pyridines which are apt for further elaborations. The transformation was amenable to gram-scale synthesis.
Collapse
Affiliation(s)
- Ling Lin
- Department of Chemistry, Jinan University, Guangzhou, 510632China
| | - Xiaoguang Chen
- Department of Chemistry, Jinan University, Guangzhou, 510632China
| | - Junhao Zhao
- Department of Chemistry, Jinan University, Guangzhou, 510632China
| | - Suitao Lin
- Department of Chemistry, Jinan University, Guangzhou, 510632China
| | - Guojian Ma
- Department of Chemistry, Jinan University, Guangzhou, 510632China
| | - Xiaojian Liao
- Department of Chemistry, Jinan University, Guangzhou, 510632China
| | - Pengju Feng
- Department of Chemistry, Jinan University, Guangzhou, 510632China
| |
Collapse
|
9
|
Lacbay CM, Menni M, Bernatchez JA, Götte M, Tsantrizos YS. Pharmacophore requirements for HIV-1 reverse transcriptase inhibitors that selectively "Freeze" the pre-translocated complex during the polymerization catalytic cycle. Bioorg Med Chem 2018; 26:1713-1726. [PMID: 29478802 DOI: 10.1016/j.bmc.2018.02.017] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2017] [Revised: 02/06/2018] [Accepted: 02/13/2018] [Indexed: 12/20/2022]
Abstract
Reverse transcriptase (RT) is responsible for replicating the HIV-1 genome and is a validated therapeutic target for the treatment of HIV infections. During each cycle of the RT-catalyzed DNA polymerization process, inorganic pyrophosphate is released as the by-product of nucleotide incorporation. Small molecules were identified that act as bioisosteres of pyrophosphate and can selectively freeze the catalytic cycle of HIV-1 RT at the pre-translocated stage of the DNA- or RNA-template-primer-enzyme complex.
Collapse
Affiliation(s)
- Cyrus M Lacbay
- Department of Chemistry, McGill University, 801 Sherbrooke Street West, Montreal, Quebec H3A 0B8, Canada
| | - Michael Menni
- Department of Biochemistry, McGill University, 3655 Sir William Osler Promenade, Montreal, Quebec H3G1Y6, Canada
| | - Jean A Bernatchez
- Department of Biochemistry, McGill University, 3655 Sir William Osler Promenade, Montreal, Quebec H3G1Y6, Canada
| | - Matthias Götte
- Department of Medical Microbiology and Immunology, University of Alberta, 6-020 Katz Group Centre, Edmonton, Alberta T6G 2E1, Canada; Department of Microbiology and Immunology, McGill University, 3775 University Street, Montreal, Quebec H3A 2B4, Canada
| | - Youla S Tsantrizos
- Department of Chemistry, McGill University, 801 Sherbrooke Street West, Montreal, Quebec H3A 0B8, Canada; Department of Biochemistry, McGill University, 3655 Sir William Osler Promenade, Montreal, Quebec H3G1Y6, Canada.
| |
Collapse
|
10
|
Segaoula Z, Leclercq J, Verones V, Flouquet N, Lecoeur M, Ach L, Renault N, Barczyk A, Melnyk P, Berthelot P, Thuru X, Lebegue N. Synthesis and Biological Evaluation of N-[2-(4-Hydroxyphenylamino)-pyridin-3-yl]-4-methoxy-benzenesulfonamide (ABT-751) Tricyclic Analogues as Antimitotic and Antivascular Agents with Potent in Vivo Antitumor Activity. J Med Chem 2016; 59:8422-40. [PMID: 27538123 DOI: 10.1021/acs.jmedchem.6b00847] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Benzopyridothiadiazepine (2a) and benzopyridooxathiazepine (2b) were modified to produce tricyclic quinazolinone 15-18 or benzothiadiazine 26-27 derivatives. These compounds were evaluated in cytotoxicity and tubulin inhibition assays and led to potent inhibitors of tubulin polymerization. N-[2(4-Methoxyphenyl)ethyl]-1,2-dihydro-pyrimidino[2,1-b]quinazolin-6-one (16a) exhibited the best in vitro cytotoxic activity (GI50 10-66.9 nM) against the NCI 60 human tumor cell line and significant potency against tubulin assembly (IC50 0.812 μM). In mechanism studies, 16a was shown to block cell cycle in G2/M phase and to disrupt microtubule formation and displayed good antivascular properties as inhibition of cell migration, invasion, and endothelial tube formation. Compound 16a was evaluated in C57BL/6 mouse melanoma B16F10 xenograft model to validate its antitumor activity, in comparison with reference ABT-751 (1). Compound 16a displayed strong in vivo antitumor and antivascular activities at a dose of 5 mg/kg without obvious toxicity, whereas 1 needed a 10-fold higher concentration to reach similar effects.
Collapse
Affiliation(s)
- Zacharie Segaoula
- Univ. Lille, Inserm, CHU Lille , UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000 Lille, France
- Oncovet Clinical Research , SIRIC ONCOLille, Parc Eurasante, Rue du Dr Alexandre Yersin, F-59120 Loos, France
| | - Julien Leclercq
- Univ. Lille, Inserm, CHU Lille , UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000 Lille, France
| | - Valérie Verones
- Univ. Lille, Inserm, CHU Lille , UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000 Lille, France
| | - Nathalie Flouquet
- Univ. Lille, Inserm, CHU Lille , UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000 Lille, France
| | - Marie Lecoeur
- Univ. Lille, CHU Lille , EA 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000 Lille, France
| | - Lionel Ach
- Univ. Lille, CHU Lille , EA 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000 Lille, France
| | - Nicolas Renault
- Univ. Lille, Inserm, CHU Lille , U995 - LIRIC - Lille Inflammation Research International Center, F-59000 Lille, France
| | - Amélie Barczyk
- Univ. Lille, Inserm, CHU Lille , U995 - LIRIC - Lille Inflammation Research International Center, F-59000 Lille, France
| | - Patricia Melnyk
- Univ. Lille, Inserm, CHU Lille , UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000 Lille, France
| | - Pascal Berthelot
- Univ. Lille, Inserm, CHU Lille , UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000 Lille, France
| | - Xavier Thuru
- Univ. Lille, Inserm, CHU Lille , UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000 Lille, France
| | - Nicolas Lebegue
- Univ. Lille, Inserm, CHU Lille , UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000 Lille, France
| |
Collapse
|
11
|
Sharma A, Luxami V, Paul K. Csp 2-O and C-C Bond Formation via Pd-Catalyzed Coupling Reaction of 2,4-Dichloroquinazoline. J Heterocycl Chem 2016. [DOI: 10.1002/jhet.2330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Alka Sharma
- School of Chemistry and Biochemistry; Thapar University; Patiala 147004 India
| | - Vijay Luxami
- School of Chemistry and Biochemistry; Thapar University; Patiala 147004 India
| | - Kamaldeep Paul
- School of Chemistry and Biochemistry; Thapar University; Patiala 147004 India
| |
Collapse
|
12
|
Le PT, Richardson PF, Sach NW, Xin S, Ren S, Xiao J, Xue L. Development of a Scalable Synthesis of 4-Aminopyrimidin-5-ol, a Versatile Intermediate. Org Process Res Dev 2015. [DOI: 10.1021/acs.oprd.5b00074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Phuong T. Le
- Pfizer Worldwide
Medicinal Chemistry, 10770 Science
Center Drive, San Diego, California 92121, United States
| | - Paul F. Richardson
- Pfizer Worldwide
Medicinal Chemistry, 10770 Science
Center Drive, San Diego, California 92121, United States
| | - Neal W. Sach
- Pfizer Worldwide
Medicinal Chemistry, 10770 Science
Center Drive, San Diego, California 92121, United States
| | - Shuibo Xin
- WuXi App Tec Co., Shanghai 200131, China
| | | | | | | |
Collapse
|
13
|
Pesti JA, LaPorte T, Thornton JE, Spangler L, Buono F, Crispino G, Gibson F, Lobben P, Papaioannou CG. Commercial Synthesis of a Pyrrolotriazine–Fluoroindole Intermediate to Brivanib Alaninate: Process Development Directed toward Impurity Control. Org Process Res Dev 2013. [DOI: 10.1021/op400242j] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Jaan A. Pesti
- Early Phase Chemical Development, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08923, United States
| | - Thomas LaPorte
- Early Phase Chemical Development, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08923, United States
| | - John E. Thornton
- Early Phase Chemical Development, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08923, United States
| | - Lori Spangler
- Early Phase Chemical Development, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08923, United States
| | - Frederic Buono
- Early Phase Chemical Development, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08923, United States
| | - Gerard Crispino
- Early Phase Chemical Development, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08923, United States
| | - Frank Gibson
- Early Phase Chemical Development, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08923, United States
| | - Paul Lobben
- Early Phase Chemical Development, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08923, United States
| | - Christos G. Papaioannou
- Early Phase Chemical Development, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08923, United States
| |
Collapse
|
14
|
Barbosa MLDC, Lima LM, Tesch R, Sant'Anna CMR, Totzke F, Kubbutat MHG, Schächtele C, Laufer SA, Barreiro EJ. Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors. Eur J Med Chem 2013; 71:1-14. [PMID: 24269511 DOI: 10.1016/j.ejmech.2013.10.058] [Citation(s) in RCA: 96] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2013] [Revised: 10/14/2013] [Accepted: 10/23/2013] [Indexed: 01/08/2023]
Abstract
Novel 2-chloro-4-anilino-quinazolines designed as EGFR and VEGFR-2 dual inhibitors were synthesized and evaluated for inhibitory effects. EGFR and VEGFR-2 are validated targets in cancer therapy and combined inhibition might be synergistic for both antitumor activity and resistance prevention. The biological data obtained proved the potential of 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors, highlighting compound 8o, which was approximately 7-fold more potent on VEGFR-2 and approximately 11-fold more potent on EGFR compared to the prototype 7. SAR and docking studies allowed the identification of pharmacophoric groups for both kinases and demonstrated the importance of a hydrogen bond donor at the para position of the aniline moiety for interaction with conserved Glu and Asp amino acids in EGFR and VEGFR-2 binding sites.
Collapse
Affiliation(s)
- Maria Letícia de Castro Barbosa
- Laboratory of Evaluation and Synthesis of Bioactive Substances (LASSBio), Federal University of Rio de Janeiro, P.O. Box 68024, 21944-971 Rio de Janeiro, RJ, Brazil(1); Graduate Program of Chemistry (PGQu), Chemistry Institute, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - Lídia Moreira Lima
- Laboratory of Evaluation and Synthesis of Bioactive Substances (LASSBio), Federal University of Rio de Janeiro, P.O. Box 68024, 21944-971 Rio de Janeiro, RJ, Brazil(1); Graduate Program of Chemistry (PGQu), Chemistry Institute, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - Roberta Tesch
- Laboratory of Evaluation and Synthesis of Bioactive Substances (LASSBio), Federal University of Rio de Janeiro, P.O. Box 68024, 21944-971 Rio de Janeiro, RJ, Brazil(1)
| | | | | | | | | | - Stefan A Laufer
- Department of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Eberhard-Karls-University Tübingen, Tübingen, Germany
| | - Eliezer J Barreiro
- Laboratory of Evaluation and Synthesis of Bioactive Substances (LASSBio), Federal University of Rio de Janeiro, P.O. Box 68024, 21944-971 Rio de Janeiro, RJ, Brazil(1); Graduate Program of Chemistry (PGQu), Chemistry Institute, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
| |
Collapse
|
15
|
Corder AL, Subedi BP, Zhang S, Dark AM, Foss FW, Pierce BS. Peroxide-shunt substrate-specificity for the Salmonella typhimurium O2-dependent tRNA modifying monooxygenase (MiaE). Biochemistry 2013; 52:6182-96. [PMID: 23906247 DOI: 10.1021/bi4000832] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Post-transcriptional modifications of tRNA are made to structurally diversify tRNA. These modifications alter noncovalent interactions within the ribosomal machinery, resulting in phenotypic changes related to cell metabolism, growth, and virulence. MiaE is a carboxylate bridged, nonheme diiron monooxygenase, which catalyzes the O2-dependent hydroxylation of a hypermodified-tRNA nucleoside at position 37 (2-methylthio-N(6)-isopentenyl-adenosine(37)-tRNA) [designated ms(2)i(6)A37]. In this work, recombinant MiaE was cloned from Salmonella typhimurium , purified to homogeneity, and characterized by UV-visible and dual-mode X-band EPR spectroscopy for comparison to other nonheme diiron enzymes. Additionally, three nucleoside substrate-surrogates (i(6)A, Cl(2)i(6)A, and ms(2)i(6)A) and their corresponding hydroxylated products (io(6)A, Cl(2)io(6)A, and ms(2)io(6)A) were synthesized to investigate the chemo- and stereospecificity of this enzyme. In the absence of the native electron transport chain, the peroxide-shunt was utilized to monitor the rate of substrate hydroxylation. Remarkably, regardless of the substrate (i(6)A, Cl(2)i(6)A, and ms(2)i(6)A) used in peroxide-shunt assays, hydroxylation of the terminal isopentenyl-C4-position was observed with >97% E-stereoselectivity. No other nonspecific hydroxylation products were observed in enzymatic assays. Steady-state kinetic experiments also demonstrate that the initial rate of MiaE hydroxylation is highly influenced by the substituent at the C2-position of the nucleoside base (v0/[E] for ms(2)i(6)A > i(6)A > Cl(2)i(6)A). Indeed, the >3-fold rate enhancement exhibited by MiaE for the hydroxylation of the free ms(2)i(6)A nucleoside relative to i(6)A is consistent with previous whole cell assays reporting the ms(2)io(6)A and io(6)A product distribution within native tRNA-substrates. This observation suggests that the nucleoside C2-substituent is a key point of interaction regulating MiaE substrate specificity.
Collapse
Affiliation(s)
- Andra L Corder
- Biophysical/Bioinorganic Group and ‡Synthetic Organic Group, Department of Chemistry and Biochemistry, College of Science, The University of Texas at Arlington , Arlington, Texas 76019, United States
| | | | | | | | | | | |
Collapse
|
16
|
Sun J, Zhang SJ, Li HB, Zhou W, Hu WX, Shan S. Novel 5-Fluorouracil Derivatives: Synthesis and Cytotoxic Activity of 2-Butoxy-4-Substituted 5-Fluoropyrimidines. B KOREAN CHEM SOC 2013. [DOI: 10.5012/bkcs.2013.34.5.1349] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
17
|
Sharma A, Luxami V, Paul K. Synthesis, single crystal and antitumor activities of benzimidazole-quinazoline hybrids. Bioorg Med Chem Lett 2013; 23:3288-94. [PMID: 23611732 DOI: 10.1016/j.bmcl.2013.03.107] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2013] [Revised: 03/16/2013] [Accepted: 03/26/2013] [Indexed: 01/28/2023]
Abstract
A series of novel regioisomeric hybrids of quinazoline/benzimidazole viz. (3-allyl-2-methyl-3H-benzimidazol-5-yl)-(2-substituted-quinazolin-4-yl)-amine and (1-allyl-2-methyl-1H-benzimidazol-5-yl)-(2-substituted-quinazolin-4-yl)-amine of biological interest were synthesized. All the synthesized compounds were well characterized by (1)H and (13)C NMR as well as mass spectroscopy. The newly synthesized compounds were screened for in vitro antitumor activities against 60 tumor cell lines panel assay. A significant inhibition for cancer cells were observed with compound 9 and also more active against known drug 5-fluorouracil (5-FU) in some tumor cell lines. Compound 9 displayed appreciable anticancer activity against leukemia, colon, melanoma, renal and breast cancer cell lines.
Collapse
Affiliation(s)
- Alka Sharma
- School of Chemistry and Biochemistry, Thapar University, Patiala 147004, India
| | | | | |
Collapse
|
18
|
Reactions of Pyridines, Benzopyridines, and Azapyridines with Organomagnesiums and Organolithiums. ACTA ACUST UNITED AC 2013. [DOI: 10.1007/7081_2012_96] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/21/2023]
|
19
|
Wang H, Wen K, Wang L, Xiang Y, Xu X, Shen Y, Sun Z. Large-scale solvent-free chlorination of hydroxy-pyrimidines, -pyridines, -pyrazines and -amides using equimolar POCl₃. Molecules 2012; 17:4533-44. [PMID: 22508333 PMCID: PMC6290571 DOI: 10.3390/molecules17044533] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2012] [Revised: 03/31/2012] [Accepted: 04/06/2012] [Indexed: 11/16/2022] Open
Abstract
Chlorination with equimolar POCl3 can be efficiently achieved not only for hydroxypyrimidines, but also for many other substrates such as 2-hydroxy-pyridines, -quinoxalines, or even -amides. The procedure is solvent-free and involves heating in a sealed reactor at high temperatures using one equivalent of pyridine as base. It is suitable for large scale (multigram) batch preparations.
Collapse
Affiliation(s)
- Han Wang
- School of Chemistry and Molecular Engineering, East China University of Science and Technology, Shanghai, 200237, China
- College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai, 201620, China
| | - Kun Wen
- College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai, 201620, China
| | - Le Wang
- College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai, 201620, China
| | - Ye Xiang
- College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai, 201620, China
| | - Xiaocheng Xu
- College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai, 201620, China
| | - Yongjia Shen
- School of Chemistry and Molecular Engineering, East China University of Science and Technology, Shanghai, 200237, China
- Authors to whom correspondence should be addressed; (Y.S.); (Z.S.); Tel./Fax: +86-21-6779-1432 (Z.S.)
| | - Zhihua Sun
- College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai, 201620, China
- Authors to whom correspondence should be addressed; (Y.S.); (Z.S.); Tel./Fax: +86-21-6779-1432 (Z.S.)
| |
Collapse
|